Viktor Adalsteinsson Selected Research

TFX

1/2022

Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Viktor Adalsteinsson Research Topics

Disease

7	Neoplasms (Cancer) 02/2024 - 10/2017
1	Ovarian Neoplasms (Ovarian Cancer) 01/2022
1	Triple Negative Breast Neoplasms 01/2022
1	Adenocarcinoma 01/2018
1	Neoplasm Metastasis (Metastasis) 01/2018
1	Melanoma (Melanoma, Malignant) 10/2017

Drug/Important Bio-Agent (IBA)

4	DNA (Deoxyribonucleic Acid)IBA 02/2024 - 01/2020
3	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2018
2	Biomarkers (Surrogate Marker)IBA 02/2024 - 01/2018
1	Proteins (Proteins, Gene)FDA Link 08/2022
1	RNA (Ribonucleic Acid)IBA 08/2022
1	TFXIBA 01/2022
1	olaparibIBA 01/2022
1	AlpelisibIBA 01/2022
1	AntibodiesIBA 01/2018
1	Histocompatibility Antigens Class IIBA 10/2017
1	Immune Checkpoint InhibitorsIBA 10/2017

Therapy/Procedure

3	Therapeutics 08/2022 - 10/2017
1	Precision Medicine 01/2018